Stock Analysis
- Italy
- /
- Medical Equipment
- /
- BIT:IVN
Estimating The Intrinsic Value Of iVision Tech S.p.A. (BIT:IVN)
Key Insights
- iVision Tech's estimated fair value is €2.15 based on 2 Stage Free Cash Flow to Equity
- iVision Tech's €1.87 share price indicates it is trading at similar levels as its fair value estimate
- iVision Tech's peers are currently trading at a premium of 38% on average
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of iVision Tech S.p.A. (BIT:IVN) as an investment opportunity by taking the forecast future cash flows of the company and discounting them back to today's value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. Believe it or not, it's not too difficult to follow, as you'll see from our example!
We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.
Check out our latest analysis for iVision Tech
The Calculation
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars:
10-year free cash flow (FCF) estimate
2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
Levered FCF (€, Millions) | €330.0k | €2.05m | €2.40m | €2.66m | €2.88m | €3.07m | €3.23m | €3.37m | €3.49m | €3.61m |
Growth Rate Estimate Source | Analyst x1 | Analyst x1 | Analyst x1 | Est @ 10.83% | Est @ 8.27% | Est @ 6.48% | Est @ 5.23% | Est @ 4.36% | Est @ 3.74% | Est @ 3.31% |
Present Value (€, Millions) Discounted @ 18% | €0.3 | €1.5 | €1.5 | €1.4 | €1.3 | €1.1 | €1.0 | €0.9 | €0.8 | €0.7 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = €10m
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.3%. We discount the terminal cash flows to today's value at a cost of equity of 18%.
Terminal Value (TV)= FCF2033 × (1 + g) ÷ (r – g) = €3.6m× (1 + 2.3%) ÷ (18%– 2.3%) = €24m
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= €24m÷ ( 1 + 18%)10= €4.5m
The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is €15m. The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of €1.9, the company appears about fair value at a 13% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.
Important Assumptions
The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at iVision Tech as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 18%, which is based on a levered beta of 2.000. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for iVision Tech
- Earnings growth over the past year exceeded the industry.
- Debt is well covered by earnings.
- No major weaknesses identified for IVN.
- Current share price is below our estimate of fair value.
- Debt is not well covered by operating cash flow.
Looking Ahead:
Although the valuation of a company is important, it shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. For iVision Tech, we've compiled three fundamental elements you should further examine:
- Risks: We feel that you should assess the 5 warning signs for iVision Tech (3 don't sit too well with us!) we've flagged before making an investment in the company.
- Future Earnings: How does IVN's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. Simply Wall St updates its DCF calculation for every Italian stock every day, so if you want to find the intrinsic value of any other stock just search here.
Valuation is complex, but we're here to simplify it.
Discover if iVision Tech might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BIT:IVN
iVision Tech
Designs and produces eyeglasses, optical frames, and sunglasses in Italy.